Global Nuclear Medicine/Radiopharmaceuticals Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032

Market Overview

According to DIResearch's in-depth investigation and research, the global Nuclear Medicine/Radiopharmaceuticals market size will reach 7,587.03 Million USD in 2025 and is projected to reach 12,215.03 Million USD by 2032, with a CAGR of 7.04% (2025-2032). Notably, the China Nuclear Medicine/Radiopharmaceuticals market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.

Research Summary

Nuclear medicine is a medical specialty that combines the use of radioactive substances, known as radiopharmaceuticals, with imaging technology to diagnose and treat various diseases. Radiopharmaceuticals are specially designed drugs that contain a radioactive material, typically a radionuclide. These radionuclides emit gamma rays or positrons, which can be detected by specialized imaging equipment such as gamma cameras or PET scanners. In diagnostic nuclear medicine, patients are administered radiopharmaceuticals either orally, intravenously, or by inhalation. The radiopharmaceutical travels to specific organs or tissues based on their metabolic activity or specific affinity, allowing for the visualization and assessment of organ function, blood flow, or cellular activity. This imaging technique provides valuable information about the presence, location, and extent of diseases such as cancer, heart disease, brain disorders, and bone abnormalities. In therapeutic nuclear medicine, higher doses of radiopharmaceuticals are used for targeted radiation therapy to treat certain types of cancer by delivering radiation directly to tumor cells. Nuclear medicine and radiopharmaceuticals have revolutionized medical diagnosis and treatment by providing non-invasive, functional imaging and precise targeted therapies, leading to improved patient care and outcomes.

The major global  manufacturers of Nuclear Medicine/Radiopharmaceuticals include China Isotope & Radiation, Dongcheng Pharmaceutical Group, Jaco, Ciaeriar, Advanced Molecular-imaging Solution, Shanghai Atom Kexing, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.

This report studies the market size, price trends and future development prospects of Nuclear Medicine/Radiopharmaceuticals. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Nuclear Medicine/Radiopharmaceuticals market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.

The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Nuclear Medicine/Radiopharmaceuticals market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Nuclear Medicine/Radiopharmaceuticals industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.    

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Manufacturers of Nuclear Medicine/Radiopharmaceuticals Include:

China Isotope & Radiation

Dongcheng Pharmaceutical Group

Jaco

Ciaeriar

Advanced Molecular-imaging Solution

Shanghai Atom Kexing

Nuclear Medicine/Radiopharmaceuticals Product Segment Include:

Diagnostic

Therapeutic

Nuclear Medicine/Radiopharmaceuticals Product Application Include:

Oncology

Thyroid

Cardiology

Others

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend

Chapter 2: Global Nuclear Medicine/Radiopharmaceuticals Industry PESTEL Analysis

Chapter 3: Global Nuclear Medicine/Radiopharmaceuticals Industry Porter's Five Forces Analysis

Chapter 4: Global Nuclear Medicine/Radiopharmaceuticals Major Regional Market Size (Sales, Revenue, Price) and Forecast Analysis

Chapter 5: Global Nuclear Medicine/Radiopharmaceuticals Competitive Analysis of Key Manufacturers (Sales, Revenue, Market Share, Price, Regional Distribution and Industry Concentration)

Chapter 6: Global Nuclear Medicine/Radiopharmaceuticals Sales, Revenue, Price and Forecast by Product Type

Chapter 7: Key Company Profiles (Product Portfolio, Sales, Revenue, Price and Gross Margin)

Chapter 8: Industrial Chain Analysis, Nuclear Medicine/Radiopharmaceuticals Different Application Market Analysis (Sales and Revenue), Sales Channel Analysis

Chapter 9: Research Findings and Conclusion

Chapter 10: Methodology and Data Sources Show more